Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Amanda McIver"'
Autor:
Benjamin A. Derman, Andrew T. Stefka, Ken Jiang, Amanda McIver, Tadeusz Kubicki, Jagoda K. Jasielec, Andrzej J. Jakubowiak
Publikováno v:
Blood Cancer Journal, Vol 11, Iss 2, Pp 1-4 (2021)
Externí odkaz:
https://doaj.org/article/91b32f38a75d447da8354e045fdda7dc
Autor:
Ben A. Derman, Ajay Major, Sarah Major, Brittany D. Wolfe, Martha Gorski, Jennifer H. Cooperrider, Evangelia Andreatos, Ken Jiang, Karson Buckley, Amanda McIver, Andrew Stefka, Andrzej Jakubowiak
Publikováno v:
Blood. 140:2108-2109
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7643bd3fe33c2a1309084f2ff8592e4a
https://doi.org/10.1182/blood-2022-158643
https://doi.org/10.1182/blood-2022-158643
Autor:
Amanda McIver, Ken Jiang, Jagoda Jasielec, Andrzej Jakubowiak, Andrew T. Stefka, Benjamin A. Derman, Tadeusz Kubicki
Publikováno v:
Blood Cancer Journal, Vol 11, Iss 2, Pp 1-4 (2021)
Blood Cancer Journal
Blood Cancer Journal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c5ac7fa0cd4a77dbe89ccc3ad9c55d0
https://doi.org/10.1038/s41408-021-00418-2
https://doi.org/10.1038/s41408-021-00418-2
Autor:
Ben A Derman, Ajay Major, Jacalyn Rosenblatt, David Avigan, Murtuza M. Rampurwala, Luis Alcantar, Bernadette M. Libao, Amanda McIver, Evangelia Andreatos, Sarah Major, Brittany Wolfe, Martha Gorski, Theodore G. Karrison, Andrew Stefka, Andrzej Jakubowiak
Publikováno v:
Blood. 138:2759-2759
Introduction: The combination of carfilzomib, lenalidomide, and dexamethasone (KRd), with and without autologous stem cell transplantation (ASCT) is an effective regimen for newly diagnosed multiple myeloma (NDMM) (Jakubowiak et al., Blood 2012 and J
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::56d63a00b831eb0d6eb4515ed81e6955
https://doi.org/10.1182/blood-2021-151832
https://doi.org/10.1182/blood-2021-151832
Autor:
Andrzej Jakubowiak, Bernadette Libao, Sunil Narula, Evangelia Andreatos, Brittany Wolfe, Jeffrey A. Zonder, Daniel Juergens, Ankit Kansagra, David L. Grinblatt, Michael R. Bishop, Ken Jiang, Amanda McIver, Jagoda Jasielec, Benjamin A. Derman, Luis Alcantar, Shayan Rayani, Theodore Karrison, Andrew T. Stefka, Sarah Major, Megan Whelan
Publikováno v:
Journal of Clinical Oncology. 39:8011-8011
8011 Background: The addition of a monoclonal antibody to triplet induction regimens in patients (pts) with MM with intent for autologous stem cell transplant (ASCT) has resulted in higher overall and deep response rates. In this study we are investi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::95a5f8a2611cca99d0bfd461527276c8
https://doi.org/10.1200/jco.2021.39.15_suppl.8011
https://doi.org/10.1200/jco.2021.39.15_suppl.8011
Autor:
Craig E. Cole, Evangelia Andreatos, Andrzej Jakubowiak, Bernadette Libao, Christine Gleason, Brittany Wolfe, Daniel Juergens, Jagoda Jasielec, Kent A. Griffith, Donna E. Reece, Andrew T. Stefka, Sarah Major, Fabrizio Fazzi, Kathryn M. Tinari, Megan Whelan, Benjamin A. Derman, Jesus G. Berdeja, Amanda McIver, Jeff Zonder
Publikováno v:
Blood. 136:50-50
Introduction: Lenalidomide (LEN) is a cornerstone in the treatment of newly diagnosed MM both as part of induction and maintenance therapy. As a result, most patients at first or second relapse are LEN exposed/refractory creating a need for effective
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::69c1be8f0b3892ed6d958425f948410e
https://doi.org/10.1182/blood-2020-141029
https://doi.org/10.1182/blood-2020-141029
Autor:
Andrzej Jakubowiak, Amanda McIver, Sarah Major, Zachary Schlei, Sandeep Parsad, Brittany Wolfe, Jagoda Jasielec, Christine Gleason, Amin Virani, Megan Ackermann
Publikováno v:
Journal of Clinical Oncology. 38:e14030-e14030
e14030 Background: Improvements in cancer treatment, supportive care, and the approval of oral chemotherapy medications over the past decade have resulted in an increasing number of cancer patients treated in outpatient settings. Transitioning cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa7448ba58e17a4b514339985997bd65
https://doi.org/10.1200/jco.2020.38.15_suppl.e14030
https://doi.org/10.1200/jco.2020.38.15_suppl.e14030
Autor:
Amanda McIver, Andrzej Jakubowiak, Agata Turowski, Ajai Chari, Erica Severson, Shaun Rosebeck, Joseph R. Mikhael, Jeffrey A. Zonder, Jennifer Nam, Kathryn M. Tinari, Todd M. Zimmerman, Leonor A Stephens, Theodore Karrison, Tyler Hycner, Jagoda Jasielec, Craig E. Cole, Cara A. Rosenbaum
Publikováno v:
British Journal of Haematology
Selinexor, an oral Selective Inhibitor of Nuclear Export, targets Exportin 1 (XPO1, also termed CRM1). Non‐clinical studies support combining selinexor with proteasome inhibitors (PIs) and corticosteroids to overcome resistance in relapsed/refracto
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e2798c93f6b60440c07bc3531ca50a4d
https://pubmed.ncbi.nlm.nih.gov/31124580
https://pubmed.ncbi.nlm.nih.gov/31124580